63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05718856 (ClinicalTrials.gov) | April 1, 2023 | 13/11/2022 | TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in Persistent or Chronic Pediatric ITP Patients Who Failed or Relapse After Hormone Therapy | Primary Immune Thrombocytopenia (ITP) | Drug: TPO-RAs;Drug: TPO-RAs combining anti-CD 20 monoclonal antibody | Institute of Hematology & Blood Diseases Hospital | Beijing Children's Hospital;Tianjin People's Hospital;The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical University Second Hospital;The First Affiliated Hospital of Xiamen University | Not yet recruiting | 6 Years | 17 Years | All | 166 | Phase 4 | China |
| 2 | EUCTR2019-004683-22-DK (EUCTR) | 12/07/2022 | 17/05/2022 | Daratumumab as a treatment for adult immune thrombocytopenia | Daratumumab as a treatment for adult immune thrombocytopenia - The DART-study | Immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Darzalex Product Name: Daratumumab Product Code: L01FC01 INN or Proposed INN: DARATUMUMAB Other descriptive name: HUMAX-CD38 | Ostfold Hospital Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 21 | Phase 2 | Denmark;Norway | ||
| 3 | EUCTR2019-004683-22-NO (EUCTR) | 16/10/2020 | 29/04/2020 | Daratumumab as a treatment for adult immune thrombocytopenia | Daratumumab as a treatment for adult immune thrombocytopenia - The DART-study | Immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10021245;Term: Idiopathic thrombocytopenic purpura;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: daratumumab INN or Proposed INN: DARATUMUMAB Other descriptive name: HUMAX-CD38 | Ostfold Hospital Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Norway | ||
| 4 | EUCTR2014-001429-33-PL (EUCTR) | 07/12/2015 | 09/10/2015 | Study to evaluate safety and efficacy in adult subjects with ITP | Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia MedDRA version: 19.1;Level: LLT;Classification code 10036735;Term: Primary thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: anti-CD40L | Bristol-Myers Squibb International Corporation | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | United States;Canada;Poland;Australia;Russian Federation;Georgia;Moldova, Republic of | ||
| 5 | EUCTR2014-001429-33-GB (EUCTR) | 24/11/2014 | 07/10/2014 | Study to evaluate safety and efficacy in adult subjects with ITP | Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia MedDRA version: 19.0;Level: LLT;Classification code 10036735;Term: Primary thrombocytopenia;System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Anti-CD40LdAb Product Code: BMS-986004 INN or Proposed INN: N/A Other descriptive name: anti-CD40L | Bristol-Myers Squibb International Corporation | NULL | Not Recruiting | Female: yes Male: yes | 80 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Canada;Poland;United Kingdom |